COMBINATION THERAPIES COMPRISING ANTI-ERBB3 AGENTS
Disclosed are methods and compositions for inhibiting the growth of a tumor (e.g., a malignant tumor) in a subject. In particular, combination therapies for treating a tumor in a subject by co-administering either i) an effective amount of an anti-estrogen agent or ii) an effective amount of a receptor tyrosine kinase inhibitor and an effective amount of a bispecific anti-ErbB2/anti-ErbB3 antibody, and optionally an effective amount trastuzumab. Also disclosed is a bispecific anti-ErbB2/anti-ErbB3 antibody for use in the therapy of a tumor in combination with either i) an anti-estrogen agent or ii) a receptor tyrosine kinase inhibitor, and optionally in use with trastuzumab.
1 . A method of treating a subject with a malignant tumor, the method comprising co-administering to the subject:
either
i) an effective amount of an anti-estrogen agent, or
ii) an effective amount of a receptor tyrosine kinase inhibitor; and
either
iii) an effective amount of a bispecific anti-ErbB2/anti-ErbB3 antibody, or
iv) an effective amount of a bispecific anti-ErbB2/anti-ErbB3 antibody and an effective amount of trastuzumab.
2 .- 5 . (canceled)
6 . The method of claim 1 , wherein all effective amounts are either mouse effective amounts or human effective amounts.
7 .- 8 . (canceled)
9 . The method of claim 1 , wherein the co-administration to the subject does not create a drug-drug interaction-mediated toxicity in the subject.
10 . The method of claim 1 , wherein the co-administration to the subject creates a substantially additive or superadditive effect.
11 . The method of claim 1 , wherein the anti-estrogen agent is an estrogen receptor antagonist or an aromatase inhibitor.
12 . The method of claim 11 , wherein the estrogen receptor antagonist is fulvestrant or tamoxifen.
13 . The method of claim 11 , wherein the aromatase inhibitor is letrozole, exemestane, anastrozole, aminoglutethimide, testolactone, vorozole, formestane, or fadrozole.
14 . The method of claim 13 , wherein the aromatase inhibitor is letrozole.
15 . The method of claim 1 , wherein the bispecific anti-ErbB2/anti-ErbB3 antibody comprises the amino acid sequence set forth in SEQ ID NO:1.
16 . The method of claim 1 , wherein the bispecific anti-ErbB2/anti-ErbB3 antibody is chosen from the group consisting of A5-HSA-ML3.9, ML3.9-HSA-A5, A5-HSA-B1D2, B1D2-HSA-A5, B12-HSA-B1D2, B1D2-HSA-B12, A5-HSA-F5B6H2, F5B6H2-HSA-A5, H3-HSA-F5B6H2, F5B6H2-HSA-H3, F4-HSA-F5B6H2, F5B6H2-HSA-F4, B1D2-HSA-H3, and H3-HSA-B1D2.
17 . The method of claim 1 , wherein the receptor tyrosine kinase inhibitor is erlotinib, afatinib, dasatinib, gefitinib, imatinib, pazopinib, lapatinib, sunitinib, nilotinib or sorafenib.
18 . The method of claim 1 , wherein the receptor tyrosine kinase inhibitor is lapatinib.
19 . The method of claim 18 wherein the lapatinib is administered via a dosing regimen comprising a 14-day dosing schedule, and wherein the lapatinib is administered intermittently.
20 . The method of claim 19 , wherein the lapatinib is administered on days 1 to 3, 1 to 4, 1 to 5, 1 to 6, or 1 to 7 of the 14-day dosing schedule.
21 . The method of claim 20 , wherein the lapatinib is administered on days 1 to 5 of the 14-day dosing schedule.
22 . The method of claim 19 , wherein the lapatinib is administered at a dose that is between 2000 and 9000 mg/d.
23 . The method of claim 22 , wherein the dose is 3000 mg/day.
24 . The method of claim 19 , wherein the dose of lapatinib administered on day 1 of the 14-day dosing cycle comprises a loading dose.
25 . The method of claim 1 , further comprising co-administering an effective amount of capecitabine and/or cisplatin.
26 .- 41 . (canceled)
42 . An aqueous solution comprising a bispecific anti-ErbB2/anti-ErbB3 antibody at a first concentration and either i) an anti-estrogen agent at a second concentration or ii) a receptor tyrosine kinase inhibitor at a third concentration, wherein each concentration is an effective concentration and when the aqueous solution is blood plasma in a subject, the subject does not experience a toxicity that is sufficiently harmful to require a change in a therapy being administered to the subject, which toxicity is mediated by a drug-drug interaction in the subject between the bispecific anti-ErbB2/anti-ErbB3 antibody and the anti-estrogen agent or the receptor tyrosine kinase inhibitor.
43 . The aqueous solution of claim 42 , wherein the anti-estrogen agent is fulvestrant or tamoxifen.
44 . The aqueous solution of claim 42 , wherein the bispecific anti-ErbB2/anti-ErbB3 antibody comprises the amino acid sequence set forth in SEQ ID NO:1.
45 . The aqueous solution of claim 42 , wherein the bispecific anti ErbB3, anti-ErbB2 antibody is chosen from the group consisting of A5-HSA-ML3.9, ML3.9-HSA-A5, A5-HSA-B1D2, B1D2-HSA-A5, B12-HSA-B1D2, B1D2-HSA-B12, A5-HSA-F5B6H2, F5B6H2-HSA-A5, H3-HSA-F5B6H2, F5B6H2-HSA-H3, F4-HSA-F5B6H2, F5B6H2-HSA-F4, B1D2-HSA-H3, and H3-HSA-B1D2.
46 . The aqueous solution of claim 42 , wherein the receptor tyrosine kinase inhibitor is chosen from the group consisting essentially of erlotinib, afatinib, dasatinib, gefitinib, imatinib, pazopinib, lapatinib, sunitinib, nilotinib and sorafenib.
47 . The aqueous solution of claim 42 , wherein the receptor tyrosine kinase inhibitor is lapatinib.
48 . A method of inhibiting the growth of a malignant tumor comprising tumor cells, said method comprising contacting the tumor cells with the aqueous solution of claim 42 .
49 . The method of claim 1 , wherein the estrogen receptor antagonist is fulvestrant or tamoxifen.
50 .- 63 . (canceled)
64 . A method of treating a subject with a malignant tumor, the method comprising co-administering to the subject, 1) an effective amount of a bispecific anti-ErbB2/anti-ErbB3 antibody, 2) an effective amount of trastuzumab, 3) an effective amount of cisplatin, and 4) an effective amount of capecitabine.
65 . A method of treating a subject with a malignant tumor, the method comprising co-administering to the subject, 1) an effective amount of a bispecific anti-ErbB2/anti-ErbB3 antibody, 2) an effective amount of trastuzumab, and 3) an effective amount of nab-paclitaxel.